“Today’s announcement on the acquisition of ViaCyte by Vertex Pharmaceuticals represents a significant stride in cures research for the type 1 diabetes community. The coming together of two leaders in the cell-derived therapies field will undoubtedly accelerate the development of VX-880 by combining their resources, technologies, intellectual property, and more.

JDRF is a proud supporter of both Vertex and ViaCyte and will continue to support emerging and transformative research of disease-modifying therapies that put us on the critical pathway to preventing and ultimately curing T1D.”

-JDRF